**Case Report**

**Mediastinal Mass in a Brain Tumor Patient Treated with Chemotherapy: Lymphoma after Temozolomide**

Austin Dixon, MD, MBA*, Bennett Chin, MD, Matthew McKinney, MD

Duke University Hospital, Durham, NC 27710

*Corresponding author: Austin Dixon, MD, MBA, Duke University Hospital, Durham, NC 27710; Tel: (919)684-7289; Fax: (919)684-715; Email: austin.x.dixon@duke.edu

Received: March 28, 2019; Accepted: April 04, 2019; Published: April 20, 2019.

**Abstract**

Patients with brain tumors are frequently treated with combination chemotherapy and radiation therapy. Alkylating agents, such as Temozolomide, have known carcinogenic effects and are associated with secondary malignancies. This case illustrates the astrocitoma patient treated with Temozolomide presenting with an unknown mediastinal mass, with lymphoma being the most likely diagnosis.

**Keywords:** Temozolomide, brain tumor, astrocytoma, secondary malignancy, Fluorodeoxyglucose (FDG) PET / CT, lymphoma

**References**


**Case Report**

Figure 1. A 41-year-old male with a history of brain tumor and prior chemotherapy presented with numerous symptoms including back pain. He underwent tumor resection resulting in a pathologic diagnosis of transformed astrocytoma and also received Temozolomide therapy (50 mg/m²) over approximately 4 years. Upon presentation, an MRI revealed leptomeningeal spread, and additionally, a posterior mediastinal mass. Subsequently, a PET/CT was obtained following intravenous administration of 14.2 mCi of fluorine-18 fluorodeoxyglucose (18F-FDG). This study demonstrated intense uptake in the mediastinal mass (Figure 1; A-transaxial CT; B- transaxial FDG PET; C-transaxial fused PET / CT; D-maximum intensity projection FDG PET).

Biopsy confirmed lymphoid malignancy suspicious for Hodgkin’s disease. Brain tumor therapies with radiation and Temozolomide have demonstrated clinical efficacy [1]. The differential diagnosis for a secondary malignancy in patients with brain malignancies treated with Temozolomide includes hematologic malignancies, however, the only solid malignancy previously reported is lymphoma [2–10]. A recent literature review demonstrated 5 reported cases of lymphoma [7]. All of the other 12 patients either had myelodyplasia or aplastic anaemia [7].

Metastatic disease from primary brain tumors outside of the nervous system is extremely uncommon occurring in <2% of the cases; this is attributed to physical barriers including the dura mater and the thickened basement membrane of the blood vessels [11]. In the clinical context of a brain tumor previously treated with Temozolomide, and a suspected extracranial malignant tumor by FDG PET / CT, lymphoma is the primary diagnostic consideration.